VetDC Announces New TANOVEA®-CA1 Publication, State of the Art Presentation at VCS 2017 Annual Conference

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology.  Data from this publication and several new VetDC-sponsored studies was prominently featured in a State … Keep Reading